CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
But statins are loose change compared to high-cost "drugs like [hepatitis drug] Solvaldi and cancer drugs," he said. "They account for some $120 billion today, but they're projected by the end of the decade to be well over $400 billion, because they all have price tags of about $100,000 or more for a course of therapy.
"We can get personal with sequencing and genomics, and we're going to be increasingly using these to get the right drug, and the right dose of that drug, to the right patient and make this much more efficient," he said.
The next day, I did hear a CFO or two grumble that Topol's smartphone-driven world is still not available to all, nor are adequate networks—cellular or otherwise—in place to drive personalized virtual or real care into all areas. Nothing new there. Technology always seems to be unevenly distributed, even in the U.S.
But even if only a fraction of what Topol expects to happen happens, it's still going to be more intriguing and turbulent in healthcare than ever. He practically dared the assembled healthcare systems to take some bolder steps. We will see if any of them take his advice.
Scott Mace is senior technology editor at HealthLeaders Media.
- 12 Hires to Keep Your Hospital Out of Trouble
- Meaningful Use Payment Adjustments Begin
- Ratcheting Up Patient Experience Has a Downside
- 'Mega Boards' Could be Rural Healthcare Disruptor
- HL20: Lee Aase—Who's Behind @MayoClinic
- 1 in 5 Eligible Hospitals Penalized for HACs
- Taming Time and Moving Healthcare Data
- HL20: Sam Foote, MD—The Courage to Speak Up
- HL20: Derek Angus, MD—An Intense Focus on Care
- HL20: Anne Wojcicki—Unlocking Consumer Access to Genetics